首页> 外文期刊>Pituitary >Cephalocaudal tumor diameter is a predictor of diabetes insipidus after endoscopic transsphenoidal surgery for non-functioning pituitary adenoma
【24h】

Cephalocaudal tumor diameter is a predictor of diabetes insipidus after endoscopic transsphenoidal surgery for non-functioning pituitary adenoma

机译:头皮瘤肿瘤直径是非功能性垂体腺瘤内镜晶状体手术后糖尿病患者的预测因子

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose Diabetes insipidus (DI) develops commonly after endoscopic transsphenoidal surgery (ETS). We retrospectively investigated the incidence, onset, duration and predictors of DI after ETS in patients with non-functioning pituitary adenoma (NFPA). Methods A total of 168 patients who underwent ETS to remove NFPAs were included. Various perioperative data on demographics, comorbidities, previous treatments, perioperative hormone deficiencies, tumor characteristics, surgery, anesthesia, intraoperative fluid balance, perioperative laboratory findings, postoperative complications, readmission and hospital length of stay were collected and analyzed. Patients were diagnosed with DI and treated with desmopressin when they showed urine output > 5 mL/kg/hr with a serum sodium concentration > 145 mmol/L or an increase >= 3 mmol/L in serum sodium concentration between two consecutive tests after surgery. DI was considered permanent when desmopressin was prescribed for > 6 months after surgery. Results Seventy-seven (45.8%) patients experienced postoperative DI and 10 (6.0%) patients suffered from permanent DI. The median onset of DI and the median duration of transient DI were postoperative day 1 and 5 days, respectively. In multivariable logistic regression analysis, cephalocaudal tumor diameter (odds ratio [95% confidence interval] 2.59 [1.05-6.36], P = 0.038) was related to postoperative DI. In receiver operating characteristic analysis, its area under the curve was 0.68 (95% confidence interval 0.59-0.76, P < 0.001). Its optimal cutoff value that maximized the sum of sensitivity and specificity for postoperative DI was 2.7 cm. Conclusions Postoperative DI was observed in 45.8% of patients undergoing ETS to remove NFPAs. A large cephalocaudal tumor diameter was predictive of postoperative DI in such patients.
机译:目的尿崩症(DI)在内镜下经蝶手术(ETS)后常见。我们回顾性调查了无功能性垂体腺瘤(NFPA)患者ETS术后DI的发生率、发病率、持续时间和预测因素。方法共有168例患者接受ETS切除NFPA。收集和分析各种围手术期数据,包括人口统计学、共病、既往治疗、围手术期激素缺乏、肿瘤特征、手术、麻醉、术中液体平衡、围手术期实验室检查结果、术后并发症、再入院和住院时间。当患者术后连续两次检测的尿量>5ml/kg/hr,血清钠浓度>145mmol/L,或血清钠浓度增加>=3mmol/L时,诊断为DI,并使用去氨加压素治疗。当术后6个月以上服用去氨加压素时,DI被认为是永久性的。结果77例(45.8%)患者术后发生DI,10例(6.0%)患者发生永久性DI。DI的中位发病时间和短暂DI的中位持续时间分别为术后第1天和第5天。在多变量逻辑回归分析中,头颈部肿瘤直径(优势比[95%置信区间]2.59[1.05-6.36],P=0.038)与术后DI相关。在受试者操作特征分析中,其曲线下面积为0.68(95%置信区间0.59-0.76,P<0.001)。使术后DI的敏感性和特异性之和最大化的最佳截止值为2.7cm。结论45.8%的ETS患者术后出现DI。头颈部肿瘤直径较大是此类患者术后DI的预测因素。

著录项

  • 来源
    《Pituitary》 |2021年第3期|共9页
  • 作者单位

    Seoul Natl Univ Coll Med Seoul Natl Univ Hosp Dept Anesthesiol &

    Pain Med 101 Daehak Ro Seoul;

    Seoul Natl Univ Coll Med Seoul Natl Univ Hosp Dept Anesthesiol &

    Pain Med 101 Daehak Ro Seoul;

    Seoul Natl Univ Coll Med Seoul Natl Univ Hosp Dept Anesthesiol &

    Pain Med 101 Daehak Ro Seoul;

    Seoul Natl Univ Coll Med Seoul Natl Univ Hosp Dept Anesthesiol &

    Pain Med 101 Daehak Ro Seoul;

    Seoul Natl Univ Seoul Natl Univ Hosp Coll Med Dept Neurosurg 101 Daehak Ro Seoul 03080 South;

    Seoul Natl Univ Coll Med Seoul Natl Univ Hosp Dept Anesthesiol &

    Pain Med 101 Daehak Ro Seoul;

    Seoul Natl Univ Coll Med Seoul Natl Univ Hosp Dept Anesthesiol &

    Pain Med 101 Daehak Ro Seoul;

    Seoul Natl Univ Seoul Natl Univ Hosp Coll Med Dept Internal Med Seoul 03080 South Korea;

    Seoul Natl Univ Seoul Natl Univ Hosp Coll Med Dept Neurosurg 101 Daehak Ro Seoul 03080 South;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

    Diabetes insipidus; Endoscopic transsphenoidal surgery; Non-functioning pituitary adenoma; Cephalocaudal tumor diameter;

    机译:糖尿病患者;内镜晶状体手术;非功能性垂体腺瘤;头皮肿瘤肿瘤直径;
  • 入库时间 2022-08-20 19:01:55

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号